Literature DB >> 8834461

Quantitative dynamics of HIV type 1 expression.

M Comar1, G Marzio, P D'Agaro, M Giacca.   

Abstract

A competitive PCR and RT-PCR procedure was developed for the quantification of HIV-1 nucleic acids in infected biological samples, with particular reference to the study of the kinetics of production of differently processed viral transcripts. The procedure entails the utilization of a competitor plasmid DNA (on DNA samples) or of an in vitro transcription product obtained from this plasmid (on RNA samples) and allows the quantification of proviral DNA, viral genomic RNA, and viral single- and multispliced mRNAs. Furthermore, it permits the direct standardization of these measurements to the amount of a reference cellular gene (for DNA quantification) or of a reference cellular transcript (for RNA quantification). This quantification procedure was used to monitor the dynamics of HIV-1 transcriptional activation in the latently infected U1 monocytic cell line after stimulation with phorbol-12-myristate-13-acetate, and in experimentally infected peripheral blood lymphocytes. Despite the biological differences between the two experimental systems, in both cases production of infectious virus is accompanied by a remarkable increase in the levels of unspliced viral mRNAs (rising up to 20,000 fold in U1 cells) and by a consequent switch in the abundance of the differently spliced transcript classes. These observations reinforce the notion that the control of infection is subjected also to posttranscriptional events and prompts for quantitative evaluation of HIV-1 transcript class abundance in infected individuals to define potential markers for disease progression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8834461     DOI: 10.1089/aid.1996.12.117

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  8 in total

Review 1.  Quantitative molecular analysis of virus expression and replication.

Authors:  M Clementi
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies.

Authors:  G Marzio; K Verhoef; M Vink; B Berkhout
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

3.  Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter.

Authors:  Marina Lusic; Alessandro Marcello; Anna Cereseto; Mauro Giacca
Journal:  EMBO J       Date:  2003-12-15       Impact factor: 11.598

4.  Dynamics of HIV-1 mRNA expression in patients with long-term nonprogressive HIV-1 infection.

Authors:  M Comar; C Simonelli; S Zanussi; P Paoli; E Vaccher; U Tirelli; M Giacca
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

5.  Changes in thymic function in HIV-positive patients treated with highly active antiretroviral therapy and interleukin-2.

Authors:  P De Paoli; M T Bortolin; S Zanussi; A Monzoni; C Pratesi; M Giacca
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

6.  Accessibility of nuclear DNA to triplex-forming oligonucleotides: the integrated HIV-1 provirus as a target.

Authors:  C Giovannangeli; S Diviacco; V Labrousse; S Gryaznov; P Charneau; C Helene
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-07       Impact factor: 11.205

7.  Transcriptional suppression of in vitro-integrated human immunodeficiency virus type 1 does not correlate with proviral DNA methylation.

Authors:  Marjorie Pion; Albert Jordan; Angelique Biancotto; Franck Dequiedt; Françoise Gondois-Rey; Sophie Rondeau; Robert Vigne; Jiri Hejnar; Eric Verdin; Ivan Hirsch
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

8.  C-C chemokines released by lipopolysaccharide (LPS)-stimulated human macrophages suppress HIV-1 infection in both macrophages and T cells.

Authors:  A Verani; G Scarlatti; M Comar; E Tresoldi; S Polo; M Giacca; P Lusso; A G Siccardi; D Vercelli
Journal:  J Exp Med       Date:  1997-03-03       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.